Trials / Completed
CompletedNCT05747430
SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)
Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Injection Pain and Corneal Epitheliopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- iRenix Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 15 centers in the United States (US).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IRX-101 | IRX-101 is a novel ocular anti-septic |
| DRUG | Providone-Iodine | 5% Providone-Iodine |
Timeline
- Start date
- 2023-02-22
- Primary completion
- 2025-03-06
- Completion
- 2026-03-31
- First posted
- 2023-02-28
- Last updated
- 2026-04-03
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05747430. Inclusion in this directory is not an endorsement.